Taking a deep dive into last week's T-cell engager data with the CEO of Janux Therapeutics

blonca9
Mar 6, 2024
1 min read

Updated: Mar 15, 2024

David Campbell explains how Janux has used masking technology to improve the profile T-cell engagers in solid tumors, and goes over the company's recent PSMA and EGFR data.

Recent Posts

See All

Checking in with MoonLake's CEO ahead of one of biotech's most closely watched trial readouts of the year - the phase 3 VELA program of sonelokimab in HS (due in Sept)

KalVista's CEO discusses today's FDA approval and commercial launch of Ekterly, the first oral therapy for treating hereditary angioedema (HAE) attacks

AI News: Singapore based Gero, a company focused on small molecules for aging conditions, launched ProtoBind-Diff, a model using amino acid sequences rather than structure models for discovery

Taking a deep dive into last week's T-cell engager data with the CEO of Janux Therapeutics

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight